Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Compatibility of the topotecan therapy in combination with carboplatin.
Ovarian Cancer
DRUG: Hycamtin
Occurrence of a DLT (Dose Limiting Toxicity), A DLT is present if a patient has a postponement due to hematologic toxicity of more than 7 days within the first four courses at dose level 0., after each cycle for up to one year
Progression-free Survival (PFS), Progression-free survival according to kaplan-meier-estimator, after every third cycle, for up to one year
The aim of the study was to confirm the tolerability of 3-day topotecan therapy in combination with carboplatin in accordance with published data and to investigate the tolerability of continued therapy until disease progression or up to a maximum of 12 months.